Mutations causing loss of function of bone morphogenetic protein receptor II (BMPRII) are found in familial and sporadic idiopathic (I) pulmonary arterial hypertension (PAH). Reduced levels of BMPRII and its co- receptor BMP-RIa, are observed in IPAH patients without a mutation and in patients with secondary PAH. We will therefore investigate how reduced BMPRII/la mediated signaling is linked to the pathological features in the pulmonary arteries (PAs) that underlie PAH. These features include loss of distal PAs associated with endothelial cell (EC) apoptosis, and progressive narrowing of the lumen of larger PAs related to smooth muscle cell (SMC) proliferation. Based on our novel preliminary findings, we propose that signaling through BMPRII/la regulates the transcriptional activity of peroxisome proliferator-activated receptor (PPAR)y. We hypothesize that PPAR? induces genes that regulate platelet derived growth factor (PDGF)-BB and Wingless (Wnt) signaling pathways. As a result, EC survival, proliferation and migration are promoted and SMC proliferation is suppressed. In the first aim of our proposal we will determine whether BMP2 induces human (h) PA EC survival, growth and motility, by a cooperative interaction between PPAR?- and IJ-catenin mediated transcription of genes. These features prevent loss of vessels in response to injury, and support regeneration.
The second aim, investigates how hPA SMC utilize PPAR? mediated regulation of target genes such as apolipoprotein (apo)E to both repress hPA MC proliferation in response to growth factors and to stimulate motility. These features are likely required in repairing vascular injury without obstruction. We will determine whether BMP2 mediated hPA SMC motility requires transcription of (i-catenin targets such as fibronectin to recruit the Wnt pathway protein Dishevelled to the cell membrane to stimulate RhoA-Rad activity. We will also simulate loss of BMPRII function by RNA interference, to determine whether PPAR? agonists can restore hPA EC proliferation and migration, and hPA SMC suppression of proliferation in response to growth factors.
Our third aim i s to pursue our observation that a transgenic mouse with selective deletion of PPAR? in SMC has PAH. We will determine whether during chronic hypoxia, loss of PPAR? heightens proliferation of SMC and worsens PAH and whether impaired SMC apoptosis impedes regression of PAH upon return to room air. We will also investigate whether a mouse with selective deletion of PPAR? in EC also has severe PAH during chronic hypoxia associated with impaired EC survival and loss of vessels and whether persistent PAH upon return to room air is related to impaired EC proliferation and vascular regeneration. The proposed studies provide mechanistic links between impaired BMPRII/ia function and PAH and may encourage investigation of PPAR? agonists as a treatment option for PAH.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL087118-02
Application #
7596418
Study Section
Respiratory Integrative Biology and Translational Research Study Section (RIBT)
Program Officer
Moore, Timothy M
Project Start
2008-04-01
Project End
2012-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
2
Fiscal Year
2009
Total Cost
$565,216
Indirect Cost
Name
Stanford University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zamanian, Roham T; Hedlin, Haley; Greuenwald, Paul et al. (2018) Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 197:788-800
Miyagawa, Kazuya; Shi, Minyi; Chen, Pin-I et al. (2018) Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1 Mediated Metabolic and Epigenetic Changes. Circ Res :
Bonnet, Sébastien; Provencher, Steeve; Guignabert, Christophe et al. (2017) Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 195:583-595
Newman, John H; Rich, Stuart; Abman, Steven H et al. (2017) Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med 195:1661-1670
Chen, Pin-I; Cao, Aiqin; Miyagawa, Kazuya et al. (2017) Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight 2:e90427
Hopper, Rachel K; Moonen, Jan-Renier A J; Diebold, Isabel et al. (2016) In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation 133:1783-94
Vattulainen-Collanus, Sanna; Akinrinade, Oyediran; Li, Molong et al. (2016) Loss of PPAR? in endothelial cells leads to impaired angiogenesis. J Cell Sci 129:693-705
Spiekerkoetter, Edda; Sung, Yon K; Sudheendra, Deepti et al. (2015) Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 192:254-7
Diebold, Isabel; Hennigs, Jan K; Miyagawa, Kazuya et al. (2015) BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. Cell Metab 21:596-608
de Jesus Perez, Vinicio; Yuan, Ke; Alastalo, Tero-Pekka et al. (2014) Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug Discov Today 19:1270-6

Showing the most recent 10 out of 22 publications